11/13/2025
We’re proud to highlight Saundra Maass-Robinson, MD, Principal Investigator at CenExel Decatur, who was recently featured in an article by Georgia Public Broadcasting discussing an innovative clinical trial exploring MM120 — a form of lysergide D-tartrate (L*D) — as a potential treatment for generalized anxiety disorder (GAD).
GAD affects millions of people, yet long-lasting treatment options with minimal side effects remain limited. As Dr. Maass-Robinson shared in the interview, “we really don't have any products on the market that give a sustained effect and control of the anxiety without a lot of potential side effects.”
The ongoing Phase 3 study investigates whether MM120 can offer the stability and relief patients need. With highly controlled dosing environments, onsite medical oversight, and dedicated session monitors, our team at CenExel Decatur is committed to ensuring participant safety while advancing breakthrough research in mental health.
We’re grateful for Dr. Maass-Robinson’s leadership and for the opportunity to contribute to research that could reshape the future of anxiety treatment.
Read the full article: https://www.gpb.org/news/2025/11/12/study-in-atlanta-treats-generalized-anxiety-disorders-form-of-lsd-psychedelic
Learn more or see if you qualify for the trial: https://anxietyresearchstudy.com